Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Catharine S. Leahy"'
Autor:
Alex K. Shalek, Peter S. Dennis, Kristen E. Stevenson, Andrew W. Navia, Peter S. Winter, Mahnoor Mirza, Haley Strouf, Nolawit Mulugeta, Nicholas L. Calistri, Kay Shigemori, Nezha Senhaji, Jennyfer Galvez-Reyes, Laura L. Bilal, Mark L. Stevens, Scott R. Manalis, David M. Weinstock, Alejandro J. Gupta, Alex Van Scoyk, Foster Powers, Catharine S. Leahy, Robert J. Kimmerling, Huiyun Liu, Mark A. Murakami, Kristen L Jones
Publikováno v:
Cancer Research. 80:IA20-IA20
Targeted inhibitors of essential oncogenic kinases induce high rates of clinical response but cure few patients due to the persistence of minimal residual disease (MRD). BCR-ABL mutant leukemias are a classic example of this paradigm where patients u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a39c0cc185d741942493ae5bfa2977f
https://doi.org/10.1158/1538-7445.tumhet2020-ia20
https://doi.org/10.1158/1538-7445.tumhet2020-ia20
Autor:
Zhengnian Li, Katherine A. Donovan, Sara N. Morrow, Eric S. Fischer, Dennis Dobrovolsky, Eric S. Wang, Tyler B. Faust, Nathanael S. Gray, David M. Weinstock, Guang Yang, Catharine S. Leahy, Steven P. Treon, Radosław P. Nowak
Publikováno v:
Blood. 133(9)
The covalent Bruton tyrosine kinase (BTK) inhibitor ibrutinib is highly efficacious against multiple B-cell malignancies. However, it is not selective for BTK, and multiple mechanisms of resistance, including the C481S-BTK mutation, can compromise it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd3a0603af67fd0c71035a6837f3903e
https://pubmed.ncbi.nlm.nih.gov/30819777
https://pubmed.ncbi.nlm.nih.gov/30819777
Autor:
Mark A. Murakami, Peter S. Winter, Andrew W. Navia, Laura L. Bilal, Haley Strouf, Kay Shigemori, Alejandro Gupta, Mahnoor Mirza, Catharine S. Leahy, Nick Calistri, Kristen Jones, Alexandra Van Scoyk, Huiyun Liu, Foster Powers, Robert Kimmerling, Mark Stevens, Kristen E. Stevenson, Scott R. Manalis, David M. Weinstock, Alex K. Shalek
Publikováno v:
Cancer Research. 79:2450-2450
Targeted inhibitors of oncogenic kinases have transformed cancer therapy by inducing high rates of clinical response across diverse tumor types, yet they cure few patients due to the persistence of minimal residual disease (MRD), which seeds relapse.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42a129f034130a3aec1c6b1ea8d04eb9
https://doi.org/10.1158/1538-7445.am2019-2450
https://doi.org/10.1158/1538-7445.am2019-2450